Imaxio, an immunology focused French biotech has recently founded a sister organization named Osivax which is all set to develop a number of clinical and preclinical vaccine candidates based on its OligoDOM technology.
The OligoDOM technology is a pro-immunogenic antigen re-engineering technology developed over the last 15 years by Imaxio . It is protected by a portfolio of 4 patent families, now owned by Osivax.
The biotech founded by Mr. Alexandre Le Vert (CEO), Dr. Florence Nicolas (Development Director) and Dr. Fergal Hill (Chief Scientific Officer), which already has a malaria vaccine in Phase I trial and an influenza vaccine expected to the clinic in 2018 has just closed a €2.7M seed funding round. Additionally, Osivax says it has in pipeline, a bunch of other immunotherapy candidates.
A serious competitor in the market now could be the UK-based Kymab, which is currently in the process of developing a number of vaccine candidates based on its humanized Kymouse.
“The creation of Osivax and this fundraising are relevant enablers to accelerate the 15 years research performed within Imaxio. Osivax has got the right team, the right focus and the right funding to accelerate the development of the oligoDOM-based pipeline, starting with the Influenza candidate which should enter the clinic in early 2018” says
